Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC)

被引：0
|
作者：
Smith, I. E.
Biganzoli, L.
Cortes-Funes, H.
Stroyakovskiy, D.
Franke, F. A.
Chlistalla, A.
Pierga, J-Y
Thomssen, C.
Pritchard, K.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Hosp Prato, Tuscany Canc Inst, Sandro Pitigliani Med Oncol Unit, Prato, Italy
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] City Clin Oncol Hosp, Moscow, Russia
[5] Hosp Caridade Ijui, Ijui, Brazil
[6] F Hoffmann La Roche Ltd, Basel, Switzerland
[7] Inst Curie, Paris, France
[8] Univ Halle Wittenberg, Halle, Germany
[9] Toronto Sunnybrook Reg Canc Ctr, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：286S / 286S
页数：1
相关论文
共 50 条
  • [21] CECILIA: AN OPEN-LABEL GLOBAL SAFETY STUDY EVALUATING BEVACIZUMAB, CARBOPLATIN AND PACLITAXEL THERAPY IN PATIENTS WITH METASTATIC, RECURRENT OR PERSISTENT CERVICAL CANCER (CC)
    Redondo, A.
    Colombo, N.
    McCormack, M.
    Nogueira-Rodrigues, A.
    Martin, N.
    Bastiere-Truchot, L.
    Gonzalez-Martin, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 201 - 201
  • [22] Effectiveness and safety in very elderly patients treated by bevacizumab plus chemotherapy in 1st-line therapy of metastatic colorectal cancer: results of etna, a French cohort study
    Fourrier-Reglat, A.
    Rouyer, M.
    Benichou, J.
    Balestra, A.
    Lassalle, R.
    Grelaud, A.
    Noize, P.
    Smith, D.
    Ravaud, A.
    Moore, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 51 - 51
  • [23] Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVAIDO phase III study
    Chan, A.
    Vanlemmens, L.
    Conte, P. F.
    Beith, J.
    Samonigg, H.
    Verma, S.
    Srimuninnimit, V
    Martoni, A.
    Miles, D. W.
    CANCER RESEARCH, 2009, 69 (02) : 114S - 114S
  • [24] QUALITY OF LIFE (QOL) AMONG PATIENTS (PTS) WITH LOCALLY RECURRENT (LR) OR METASTATIC BREAST CANCER (MBC): RESULTS FROM THE PHASE III AVADO STUDY OF FIRST-LINE BEVACIZUMAB (BV) PLUS DOCETAXEL (D) VERSUS D PLUS PLACEBO (PL)
    Greil, R.
    Im, Y. H.
    Pienkowski, T.
    Wardley, A.
    Awada, A.
    Ciruelos, E.
    Freitas-Junior, R.
    Fumoleau, P.
    Sriuranpong, V.
    Miles, D. W.
    ANNALS OF ONCOLOGY, 2008, 19 : 67 - 67
  • [25] An open-label study of sunitinib (SU) plus exemestane (E) in the first-line treatment of hormone receptor (HR)-positive metastatic breast cancer (MBC)
    Ahlgren, P.
    Thirlwell, M.
    O'Regan, R.
    Mormont, C.
    Levesque, L.
    Gaspo, R.
    Woloj, M.
    Bello, A.
    Martell, B.
    Leyland-Jones, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [26] Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recyrrent or metastatic breast cancer (MBC): Interim safety analysis
    Borson, R.
    Harker, W. G.
    Reeves, J. E.
    Bromund, J.
    Zhao, L.
    Tai, D. F.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [27] A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
    Dieras, V.
    Jassem, J.
    Dirix, L. Y.
    Guastalla, J. P.
    Bono, P.
    Hurvitz, S. A.
    Goncalves, A.
    Romieu, G.
    Limentani, S. A.
    Jerusalem, G. H. M.
    Lakshmaiah, K.
    Roche, H. H.
    Sanchez-Rovira, P.
    Pienkowski, T.
    Segui-Palmer, M. A.
    Li, A.
    Sun, Y.
    Pickett-Gies, C. A.
    Wildiers, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Combination of Paclitaxel and Bevacizumab without or with Capecitabine as First-Line Treatment of HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): First Results from a Randomized, Multicenter, Open-Label, Phase II Study of the Dutch Breast Cancer Trialists' Group (BOOG).
    Lam, S. W.
    de Groot, S. M.
    Honkoop, A. H.
    Jager, A.
    ten Trje, A. J.
    Bos, M. M. E. M.
    Linn, S. C.
    van den, Bosch J.
    Nortier, J. W. R.
    Braun, J. J.
    de Graaf, H.
    Portielje, J. E. A.
    Los, M.
    Gooyer, D. D.
    van Tinteren, H.
    Boven, E.
    CANCER RESEARCH, 2011, 71
  • [29] The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (ATC).
    Awada, A.
    Leung, A. C. F.
    Zhao, C.
    Hannah, A. L.
    Perez, E. A.
    CANCER RESEARCH, 2011, 71
  • [30] Effectiveness and Safety in Very Elderly Patients Treated by Bevacizumab (BV) Plus Chemotherapy in 1st-Line Therapy of Metastatic Colorectal Cancer: Results of ETNA, a French Cohort Study
    Fourrier-Reglat, Annie
    Rouyer, Magali
    Noize, Pernelle
    Balestra, Aurelie
    Lassalle, Regis
    Bernard, Marie-Agnes
    Ravaud, Alain
    Smith, Denis
    Moore, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S239 - S239
12345